← Back to Clinical Trials
Recruiting NCT05498675
Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study
Trial Parameters
Condition Sacubitril/Valsartan
Sponsor Beijing Friendship Hospital
Study Type OBSERVATIONAL
Phase N/A
Enrollment 180
Sex ALL
Min Age 18 Years
Max Age 70 Years
Start Date 2021-09-01
Completion 2026-12-31
All Conditions
Interventions
Sacubitril / Valsartan Oral Tablet [Entresto]ACEI/ARB
Brief Summary
The purpose of this study is to investigate the effect of sacubitril/valsartan on cardiac function assessed by cardiac magnetic resonance (CMR) in hypertensive patients stratified by BMI.
Eligibility Criteria
Inclusion Criteria: * Patients with essential hypertension * 18-70 years old * No major barriers to provide written consent Exclusion Criteria: * Secondary hypertension, except because of sleep apnea * cardiovascular disease (myocardial infarction, heart failure, stroke or coronary revascularization) within 6 months * Severe concomitant diseases (autoimmune disease, malignancy, late stage of liver diseases, respiratory diseases and digestive diseases) * Unable to understand or comply with the study procedures